Introduction
Efforts to expand HIV infection treatment programmes in sub-Saharan Africa (SSA) have demonstrated improvement in access to HAART. The estimated number of HIV-infected individuals in low-income and middleincome countries (LMICs) on antiretroviral therapy (ART) increased five-fold from 1.3 million in 2006 to over 6.6 million in 2013 [1, 2] , with robust and sustained immune responses for those patients who remain on treatment, especially when starting ART with higher baseline CD4 þ cell counts [3] . Overall AIDS-related morbidity and death have declined markedly in countries where access to ART has significantly improved [3] [4] [5] . However, the persistent problem of ART initiation in the advanced stages of HIV infection threatens to limit the full potential of HIV scale-up programmes in SSA [6] , and is associated with high mortality rates after ART initiation and further HIV transmission [6] [7] [8] . The excess mortality is due in large part to ART initiation at low CD4 þ cell counts [4] . In resource-limited settings with weak healthcare infrastructure, many operational challenges beside social, economic and clinical determinants are associated with lower CD4 þ cell count at enrollment and at ART initiation, all of which mitigate the benefit of HIV treatment programmes [9, 10] .
With an HIV prevalence of 3.0% [11] , Rwanda has been scaling up access to HIV care since 2004, and the mature national programme has achieved more than 93% ART coverage [12] with high rates of retention [13] and medication adherence with viral suppression [14] . We therefore examined the proportion of persons enrolling in HIV care and initiating ART in the advanced stages of HIV infection among patients in Kigali, Rwanda, before and after the first expansion of national ART guidelines from a CD4 þ threshold of 200 cells/ml to 350 cells/ml. In order to assess barriers and enablers to timely ART initiation in the context of high ART coverage and high median CD4 þ at ART initiation, we examined correlates of advanced HIV infection at ART initiation among persons initiating ART in 2012.
Methods

Study population and data source
The study population included HIV-infected adult patients (!15 years) enrolling in care, and initiating ART at five urban HIV care clinics [Women's Equity in Access to Care and Treatment, Carrefour, Bethsaida, Kicukiro and Makasa] in Kigali from January 2003 to June 2012 participating in the International epidemiologic Databases to Evaluate AIDS (IeDEA) consortium (http:// www.iedea.org). We used electronic patient-level data collected as part of routine service delivery from clinics that are part of the national HIV care and treatment programme in Rwanda. Patient information at enrollment and/or ART initiation was collected routinely by nurses and trained data clerks using standard national patient medical records and then entered into an electronic database. Data were de-identified prior to being shared with researchers for analysis.
Outcome definition
We defined advanced HIV disease at enrollment into care or ART initiation as either having a CD4 þ cell count of less than 200 cells/ml or a WHO stage IV condition at the time of enrollment or ART initiation, respectively. The CD4 þ cell count at ART initiation included CD4 þ results measured up to 90 days before or 30 days after the date of ART initiation, with priority given to CD4 þ cell counts prior to ART initiation and otherwise closest to the ART initiation date. A small proportion of patients (<5%) who did not have WHO staging information and CD4 þ cell counts at enrollment into care or ART initiation were included in analyses and categorized as missing/unknown.
HIV-infected patients who enrolled into care, and were not eligible for treatment were offered various services that included monitoring of their CD4 þ cell counts on a 6-month basis and prophylaxis for opportunistic infections and prevention of mother-to-child transmission (PMTCT) according to guidelines in place at the time. Patients received HIV voluntary counseling and testing (VCT) or provider-initiated voluntary counseling and testing (PVCT) and were enrolled into care. Enrollment into care often occurred at the same testing site as all five study clinics routinely offer HIV prevention, diagnostic and treatment services including CD4 þ cell count determination. Patients who enrolled into care from 2003 to 2006 were considered ART eligible under the 2004 national ART guidelines in Rwanda [12] (WHO stage IV diagnosis irrespective of CD4 þ cell count, or a WHO clinical stage of III with a CD4 þ cell count of <350 cells/ml, or WHO stage I or II with a CD4 þ cell count of <200 cells/ml). Patients enrolled into care from 2007 to 2011 were considered ARTeligible under the 2007 national guidelines (WHO stage IVor a CD4 þ cell count of less than 350 cells/ml irrespective of WHO stage). Patients enrolling into care in 2012 were considered ART eligible under the 2012 national ART guidelines (CD4 þ cell count of <500 cells/ml irrespective of WHO stage). Women who were pregnant and not already on ART were referred to PMTCT services. Also, those with active tuberculosis disease, WHO stage III and IV and, beginning in 2012, those in a serodiscordant relationships were initiated on ART regardless of their CD4 þ cell count.
Statistical analysis
We examined trends in the median CD4 þ cell count and percentage of patients enrolling in care and initiating ART with CD4 þ cell count more than 200, more than 350 and more than 500 cells/ml during 2003-2012, before and after the first expansion of ART eligibility criteria in the national guidelines. Relative risk (RR) ratios for the proportion of patients with advanced disease at enrollment into care and ART initiation were calculated, comparing the risk before 2007 with that in 2011-2012 within patient characteristics. For patients initiating ART in 2011-2012, we examined factors associated with advanced HIV disease (CD4 þ <200 cells/ ml or WHO stage IV). Adjusted odds ratios (AOR) and 95% confidence intervals (CIs) were generated using generalized estimating equations to account for clustering of patients within sites. Statistical analyses were carried out using SAS version 9.2 (SAS Institute, Cary, North Carolina, USA).
Ethical review
Ethical approvals for this study were obtained from the Rwandan National Ethics Committee and the Institutional Review Board of Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Results
Characteristics of patients at enrollment into care and at antiretroviral therapy initiation Sociodemographic characteristics of the 6326 patients at least 15 years enrolled into care from 2003 to 2012 are presented in Table 1 . Median age was 35 years [interquartile range (IQR): 29-42] and 62% were women, of whom 3.4% were pregnant. Twenty percent of patients were married and 64% were enrolled through a voluntary testing and counseling center. About 71% (n ¼ 4486) of patients initiated ART during the study follow-up to 2012, with 2.0% of women (n ¼ 87) pregnant at ART initiation.
The proportion of patients with advanced HIV disease enrolling into care and initiating ART was 23.8 and 45.7%, respectively ( Table 2) . Median CD4 þ cell count for all patients at enrollment was 349 cells/ml (IQR: 194-543) and for those who initiated ART was 211 cells/ml (IQR: 131-300) at the point of ART initiation. For those with data available at enrollment (n ¼ 5280), the proportion of patients with WHO stage III or IV at enrollment into care was 21% compared with 27% at ART initiation ( Table 2 ). Approximately 48% of all patients were immediately eligible for ART at enrollment based on the Rwanda national guidelines in effect at the time of their enrollment.
Trends in CD4 R cell count among patients at enrollment into care and at antiretroviral therapy initiation From 2003 to 2012, there was a near doubling in median CD4 þ cell count at enrollment in care for all patients from 185 (IQR: 109-378) in 2003 to 340 cells/ml (IQR: 184-480) in 2012 ( Fig. 1a ). Women had higher median CD4 þ cell counts at enrollment than men for the entire time period of 2003-2012. Overall, the median CD4 þ cell count at enrollment into care for men and women were 317 cells/ml (IQR: 168-508) and 372 cells/ml (IQR: 217-571) respectively, P < 0.001. Men on average initiated ART at a lower CD4 þ cell count than women; 198 cells/ml, (IQR 120-290) vs. 223 cells/ml (IQR: 140-305) for men and women, respectively, P < 0.001 (data not shown). The median CD4 þ cell count at ART initiation increased steadily during 2003-2012. During the first Rwandan national guidelines expansion in 2007-2008, which increased the CD4 þ cell count for treatment initiation to less than 350 cells/ml, the median CD4 þ cell count for patients in our study increased from 183 to 246 cells/ml within 1 year of national guideline expansion, and ultimately reached 293 cells/ml in 2011 ( Fig. 1b ).
The proportion of patients who initiated ART at CD4 þ cell count of more than 200, more than 350 and more than 500 cells/ml over time is shown in Fig. 1c . Whereas there was a large increase in the proportion of patients initiating ART with CD4 þ cell count of greater than 200 cells/ml from 38.2 to 67.3% after the 2007 national guideline expansion, the proportion of patients in 2012 with CD4 þ cell count of greater than 350 cells/ml at ART initiation was 19.7%. Patients initiating ART at a CD4 þ cell count of greater than 500 cells/ml rose from 5.3% in 2011 to 9.8% in 2012 during the year where national guidelines expanded to include treatment for all patients with a CD4 þ cell count of less than 500 cells/ml. The median CD4 þ cell counts of patients enrolling in HIV care who ultimately initiated ART appeared to increase more in women than men, with an overall median CD4 þ cell count of 377 cells/ml by 2012, with women at 430 cells/ml vs. men 322 cells/ml P < 0.001 (data not shown). 
Discussion
Our analyses showed substantial improvements in the median CD4 þ cell counts at ART initiation in our sample of five clinics from Rwanda, where the ART coverage has risen to over 93% [12] and national ART eligibility guidelines have been expanded, often in advance of other countries in the region. The five HIV clinics included in our study comprised of two private clinics and three government-owned clinics where IeDEA programmes initially started. They are among the HIV clinics in the country with a large volume of patients, and are located in both urban and periurban settings. The median CD4 þ cell count at ART initiation in our study of HIV-infected Rwandan patients is higher than reported in other studies in the region [10, 15, 16] . A global analysis of data from 48 countries, including those in North America, Europe, and SSA, found that in 2009 the United States had the highest mean CD4 þ cell count at ART initiation (307 cells/ml) followed, remarkably, by Rwanda (287 cells/ml) [17, 18] . Given this and other HIV programmatic scale-up successes in Rwanda [13, 14, 19] , there are likely important lessons to be learned by comparing Rwanda's experience with those of other countries in SSA.
Surprisingly, although this was an analysis of specific HIV sites in an urban setting, our reported median CD4 þ cell count at ART initiation reached up to 293 cells/ml in 2011, and is considerably higher than the recent estimates of median CD4 þ of 155 cells/ml in 2009 from clinical sites in various LMICs [18] . Therefore, our observation of higher median CD4 þ cell count at ART initiation is different from the consistently reported low median CD4 þ cell count at ART initiation in other SSA settings [3, 4, [7] [8] [9] [10] . One recent study of trends in CD4 þ cell count at ART initiation in four SSA studies, including Rwanda, found an increase in median CD4 þ 72 AIDS 2015, Vol 29 No 1 [20] . We believe the larger increases in median CD4 þ cell count at ART initiation in Rwanda demonstrates rapid achievement of very high ART programme coverage, achievable in part because of lower HIV prevalence than that of other East and Southern African countries. Systematically identifying specific reasons for this progress that may be replicable in other settings is an important research priority for the region.
We observed an overall improvement in the timeliness of ART initiation, with risk of initiating ART with CD4 þ cell count less than 200 cells/ml falling from 58.7% in 2007 to less than 32.0% in 2008-2012. More timely ART initiation has several benefits associated with improved individual patient survival, lower burden on the healthcare system, and decreased likelihood of onward HIV transmission [15, 21] . The observed increase in the proportion of people initiating ART with CD4 þ cell count more than 200 cells/ml was restricted to those with 200< CD4 þ < 350 cells/ml is further evidence that the guideline change drove the increase. The reason for the increase followed by the decline in the median CD4 þ cell count at enrollment into HIV care beginning in 2010 is less clear, but likely because of factors outside the HIV care system such as improvements in testing coverage and linkage. For example, increases testing coverage could have the effect of identifying a large bolus of prevalent positives in the short term. Over the long term, those undiagnosed people living with HIV (PLWH) who are more marginalized and thus less likely to be tested before development of symptoms could be driving declines in the median CD4 þ cell count at enrollment (possibly representing a return to baseline/steady state).
In this study, several factors were independently associated with greater likelihood of late ART initiation in 2011/12, including male sex and older age. Other studies from SSA have also reported that men start ART at lower median CD4 þ cell count, and the rate of change in CD4 þ cell count over time is significantly lower in men than women [22] [23] [24] [25] . Our study found that the disparity persists even in Rwanda where the ART coverage is high, and that the sex difference is largely explained by men being more likely to be ART eligible (i.e. sicker) at enrollment than women, likely because of later diagnosis and/or delayed linkage to HIV care [7] . This in turn suggests that guideline changes and a strong HIV care system alone will not eliminate sex disparities in late treatment initiation, and more research is needed on how to address this important sex disparity in the timeliness of ART initiation, which appears to be worsening with time [20] .
In addition to earlier ART initiation, we observed an increase in median CD4 þ cell count at enrollment in care from 185 to 340 cells/ml. This finding is likely a result of improved timeliness in diagnosing and linking HIVpositive patients to care, and not a direct result of expanding treatment guidelines, which tend to affect the timeliness with which treatment is initiated among those already enrolled in HIV care. The finding of increasing median CD4 þ cell count at enrollment into HIV care may be explained in part by several synergistic factors associated with improved primary healthcare access in Rwanda. This includes a strong healthcare system and infrastructure which is being rapidly developed, with community-based health insurance [19, 26, 27, 28] , improved workforce skills promotion of performancebased financing and strong leadership commitment [19, 29, 30] .
Drivers of timely ART initiation include timely HIV diagnosis following infection, followed by timely linkage to care and ART initiation [7] . [31] .
It is likely that other more upstream factors are responsible for these HIV-specific outcomes. In addition to the increasing proportion of Rwandans with national community-based health insurance, Rwanda's healthcare system and infrastructure has been improving over time [19] . Despite being one of the poorest countries in the world, with approximately 63% of its population living on less than $1.25 USD per day [32] , the country has harmonized donor support for its HIV programme, retaining ownership of all developmental programmes to ensure that support funds are sustainable in the medium to long term [19, 26] . The availability of trained community health workers or animateurs de santé to deliver preventive, diagnostic and therapeutic services at each village level or Umudugudu, further help link patients to healthcare facilities in a timely manner [12, 26] .
Our study has some limitations. First, our sample was limited to patients enrolled in HIV care programmes in urban settings. Urban patients may have greater opportunity and capacity than rural patients to access HIV services, with fewer barriers to access, for instance, shorter distance to clinic, higher education and better socioeconomic demographic characteristics. Our analysis also included only sites that have electronic data systems, which may not be representative of HIV programmes without such systems. Additionally, the five urban sites included in our study are not representative of all HIV care sites in Kigali or Rwanda. Finally, the observational nature of our study limits our ability to assess and quantify any underlying causal effect of the risk factors and correlates examined.
The strengths of our study include use of routinely collected patient data from several urban private and government-owned HIV sites. This allows for analysis of routine clinical data rather than data collected for research purposes only. Secondly, our analyses include broad data for the sites over 10 years from 2003 to 2012, a period when the Rwandan national guidelines eligibility criteria for ART initiation changed in 2007-2008 from CD4 þ cell counts of less than 200 cells/ml þ/À WHO stage IV or WHO stage III with 200-350 cells/ml to CD4 þ cell counts less than 350 cells/ml irrespective of WHO stage.
In conclusion, we observed a marked increase in the median CD4 þ cell count at ART initiation, and a dramatic increase in the proportion of patients initiating ART with CD4 þ more than 200 cells/ml following the expansion of ART eligibility criteria in 2007-2008. Although the increase in the median CD4 þ cell count at ART initiation was observed in both women and men, men were significantly more likely than women to initiate ARTat lower CD4 þ cell counts, and to initiate ARTwith CD4 þ cell counts less than 200 cells/ml or WHO IV. Despite high levels of ART coverage in Rwanda, a substantial proportion of persons continue to initiate ART well below the CD4 þ thresholds specified in national guidelines, even with near universal coverage. Additional research is therefore needed on the determinants of late diagnosis, enrollment into care, and treatment initiation, even in the context of very high ART coverage. It is also important to better understand the mechanisms by which men initiate ART later than women, and to diagnose and link them to HIV care earlier through VCT and PMTCT with partner testing. As Rwanda is among the few countries in SSA with rapid HIV scale up programmes that has achieved high treatment coverage, further studies are needed to examine whether programme quality can be maintained, and to understand how best to replicate the successes of Rwanda in other settings.
